In a double-blind, randomized phase II trial (NCT00493636), the combination of sorafenib with gemcitabine or capecitabin promoted progression-free survival moderately in HER2 − breast cancer patients with manageable toxicity [129]. Here, ERBB2 is linked to breast carcinoma.